Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AusperBio to Start China Trials of Antisense Oligonucleotide for Chronic Hepatitis B Cure

publication date: Jun 30, 2023

AusperBio, a Hangzhou-Boston biotech, has been approved to start China trials of its lead drug, AHB-137, an unconjugated antisense oligonucleotide that aims to provide a functional cure for chronic hepatitis B. The company believes AHB-137 has the potential to be a backbone for a functional CHB cure, implying additional drugs will be needed. As a long-term strategy, AusperBio plans to combine its oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a range of unmet medical needs. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital